Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Aghokeng, Avelin F ^a,b   Kouanfack, Charles ^c   Eymard Duvernay, Sabrina ^b   Butel, Christelle ^b   Edoul, Ginette E ^a   Laurent, Christian ^b   Koulla Shiro, Sinata ^c   Delaporte, Eric ^b   Mpoudi Ngole, Eitel ^a   Peeters, Martine ^b  

^a Institut de Recherche pour le Developpement Cameroon   (Cameroon)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

Author keywords

Cameroon; Drug resistance; HIV 1; Resource limited country; Treatment outcome; Virological monitoring

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; THYMIDINE; VIRUS RNA; ZIDOVUDINE; ANTIRETROVIRUS AGENT; VIRUS PROTEIN;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CAMEROON; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PUBLIC HEALTH; TREATMENT OUTCOME; VIRUS LOAD; CROSS-SECTIONAL STUDY; DNA SEQUENCE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; METHODOLOGY; MISSENSE MUTATION; MOLECULAR GENETICS; RESOURCE-LIMITED COUNTRY; VIROLOGICAL MONITORING; VIROLOGY;

CAMEROON; DRUG RESISTANCE; HIV-1; RESOURCE-LIMITED COUNTRY; TREATMENT OUTCOME; VIROLOGICAL MONITORING;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAMEROON; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL PROTEINS;

MLCS; MLOWN;

EID: 84879158382     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18004     Document Type: Article

References (21)

1. Hamers RL, Schuurman R, Sigaloff KC, Wallis CL, Kityo C, Siwale M, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2011;12(4):307-17.
2. Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, Brinkhof MW, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009;23(14):1867-74.
3. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 revision. 2010 [Cited 2011 June 10]. Available from: http://wwwwhoint/entity/hiv/pub/arv/rapid-advice- artpdf.
4. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10(3):155-66.
5. Kouanfack C, Montavon C, Laurent C, Aghokeng A, Kenfack A, Bourgeois A, et al. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis. 2009;48(9):1318-22.
6. Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JB, Boyer S, et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised noninferiority trial. Lancet Infect Dis. 2011;11(11):825-33.
7. Mugyenyi P,Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375(9709):123-31.
8. Vergne L, Bourgeois A, Mpoudi-Ngole E, Mougnutou R, Mbuagbaw J, Liegeois F, et al. Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02-AG variant and disease stage. Virology. 2003;310(2):254-66.
9. Rouet F, Chaix ML, Nerrienet E, Ngo-Giang-Huong N, Plantier JC, Burgard M, et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr. 2007;45(4):380-8.
10. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol. 2000;38(11):3919-25.
11. Muwonga J, Edidi S, Butel C, Vidal N, Monleau M, Okenge A, et al. Resistance to antiretroviral drugs in treated and drug-naive patients in the Democratic Republic of Congo. J Acquir Immune Defic Syndr. 2011;1(57 Suppl):S27-33.
12. Sigaloff KC, Ramatsebe T, Viana R, Wit TF, Wallis CL, Stevens WS. Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS Res Hum Retroviruses. 2011;28(2):171-5.
13. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;53(4):480-4.
14. Dagnra AY, Vidal N, Mensah A, Patassi A, Aho K, Salou M, et al. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. J Int AIDS Soc. 2011;14:30.
15. Aghokeng AF, Vergne L, Mpoudi-Ngole E, Mbangue M, Deoudje N, Mokondji E, et al. Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther. 2009;14(3):401-11.
16. Aghokeng AF, Kouanfack C, Laurent C, Ebong E, Atem-Tambe A, Butel C, et al. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS. 2011;25(17):2183-8.
17. Hawkins CA, Chaplin B, Idoko J, Ekong E, Adewole I, Gashau W, et al. Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr. 2009;52(2):228-34.
18. Doualla-Bell F, Avalos A, Brenner B, Gaolathe T, Mine M, Gaseitsiwe S, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother. 2006;50(12):4182-5.
19. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J Clin Virol. 2008;41(4):310-3.
20. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006;20(9):F9-13.
21. Parikh UM, Bacheler L, Koontz D, Mellors JW. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol. 2006;80(10):4971-7.